Tumour

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It took place on 14 Dec, 4PM GMT, 5PM CET.  Watch on Demand […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]

Major advances have been achieved in targeted immunotherapy with significant clinical benefits for patients. However, on-target/off-tumour toxicity is still a major concern, which highlights the clinical need for better targets to improve the safety profile of immunotherapies.   On-target/off-tumour toxicity is mainly based on the expression of tumour-associated antigens (TAA) in healthy tissues under physiological conditions. New approaches have […]

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It took place on 14 Dec, 4PM GMT, 5PM CET.  Watch on Demand […]

Researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy.  Clear cell renal cell carcinoma is the most common type of kidney cancer, accounting for around 75% of cases. Treatment often includes immunotherapy […]